JP2023503167A - Ａｈｒ阻害剤およびその使用 - Google Patents

Ａｈｒ阻害剤およびその使用 Download PDF

Info

Publication number
JP2023503167A
JP2023503167A JP2022530740A JP2022530740A JP2023503167A JP 2023503167 A JP2023503167 A JP 2023503167A JP 2022530740 A JP2022530740 A JP 2022530740A JP 2022530740 A JP2022530740 A JP 2022530740A JP 2023503167 A JP2023503167 A JP 2023503167A
Authority
JP
Japan
Prior art keywords
cancer
compound
sdi
patient
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022530740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503167A5 (enExample
Inventor
アルフレッド シー． カストロ，
ジェイムズ マーティン ザ サード ノーラン，
シャオヤン ミシェル ジャン，
ジェイソン セイガー，
Original Assignee
イケナ オンコロジー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イケナ オンコロジー， インコーポレイテッド filed Critical イケナ オンコロジー， インコーポレイテッド
Publication of JP2023503167A publication Critical patent/JP2023503167A/ja
Publication of JP2023503167A5 publication Critical patent/JP2023503167A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022530740A 2019-11-26 2020-11-25 Ａｈｒ阻害剤およびその使用 Withdrawn JP2023503167A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962940514P 2019-11-26 2019-11-26
US62/940,514 2019-11-26
US202063106530P 2020-10-28 2020-10-28
US63/106,530 2020-10-28
PCT/US2020/062116 WO2021108469A1 (en) 2019-11-26 2020-11-25 Ahr inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2023503167A true JP2023503167A (ja) 2023-01-26
JP2023503167A5 JP2023503167A5 (enExample) 2023-12-04

Family

ID=73856333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022530740A Withdrawn JP2023503167A (ja) 2019-11-26 2020-11-25 Ａｈｒ阻害剤およびその使用

Country Status (11)

Country Link
US (1) US20230026232A1 (enExample)
EP (1) EP4065090A1 (enExample)
JP (1) JP2023503167A (enExample)
KR (1) KR20220125232A (enExample)
CN (1) CN115279347A (enExample)
AU (1) AU2020391451A1 (enExample)
BR (1) BR112022010143A2 (enExample)
CA (1) CA3159315A1 (enExample)
IL (1) IL293325A (enExample)
MX (1) MX2022006312A (enExample)
WO (1) WO2021108469A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
WO2021236717A1 (en) 2020-05-20 2021-11-25 Senda Biosciences, Inc. Fused imidazole derivatives as ahr antagonists
TW202421150A (zh) * 2022-09-14 2024-06-01 美商阿克思生物科學有限公司 艾魯美冷之分散體

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
EP3774767B1 (en) * 2018-04-05 2025-10-29 Beth Israel Deaconess Medical Center, Inc. Aryl hydrocarbon receptor modulators and uses thereof
KR20210151061A (ko) * 2019-03-11 2021-12-13 피티씨 테라퓨틱스, 인크. 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형

Also Published As

Publication number Publication date
AU2020391451A1 (en) 2022-06-16
EP4065090A1 (en) 2022-10-05
WO2021108469A1 (en) 2021-06-03
CA3159315A1 (en) 2021-06-03
IL293325A (en) 2022-07-01
KR20220125232A (ko) 2022-09-14
MX2022006312A (es) 2022-06-22
BR112022010143A2 (pt) 2022-08-09
CN115279347A (zh) 2022-11-01
US20230026232A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
JP7022172B2 (ja) ２－（ｔｅｒｔ－ブチルアミノ）－４－（（１Ｒ，３Ｒ，４Ｒ）－３－ヒドロキシ－４－メチルシクロヘキシルアミノ）－ピリミジン－５－カルボキサミドの製剤
US20230026232A1 (en) Ahr inhibitors and uses thereof
CN109069410A (zh) 用于治疗血液恶性肿瘤和实体瘤的idh1抑制剂
CN103735530A (zh) 吡非尼酮与药物可接受的赋型剂的胶囊制剂
JP2020533283A (ja) エンドキシフェンを製造および使用する方法
CN113853374B (zh) 具有增强的生物利用度的化合物形式及其制剂
JP2021500357A (ja) 改善されたブロモクリプチン製剤
TWI894266B (zh) 醋酸阿比特龍和尼拉帕尼之藥物配製物
JP2019529502A (ja) アルツハイマー病及びパーキンソン病を処置するための組成物及び方法
EA052058B1 (ru) Лечение рака предстательной железы с помощью комбинации абиратерона ацетата и нирапариба
CN119768155A (zh) 依曲地南的分散体
BR122023016197B1 (pt) Sal cristalino de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida, composição farmacêutica o compreendendo e uso dos mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231124

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240318